Inapill develops first‑in‑class oral small‑molecule therapeutics that modulate immune‑cell metabolism to simultaneously suppress multiple pro‑inflammatory cytokines.
Funding
Funding not disclosed
Founders
Product
Problem
Current anti‑inflammatory biologics often have limited efficacy because they target single cytokines, while patients may develop anti‑drug antibodies and require frequent injections, leading to poor compliance and resistance.
Solution
Inapill is creating orally administered small‑molecule therapeutics that act upstream of cytokine signaling by modulating immune cell metabolism. By tuning mitochondrial function, these compounds simultaneously suppress the production of multiple pro‑inflammatory cytokines, addressing cytokine redundancy. Oral delivery eliminates the need for injections, improving patient adherence and reducing the risk of anti‑drug antibody formation. The approach leverages immunometabolic research, including insights into sex‑hormone–mediated protection, to develop first‑in‑class agents for inflammatory, autoimmune, and age‑related diseases. This strategy aims to provide more consistent efficacy and a better safety profile compared with existing biologics.
Target Audience
Primary customers are pharmaceutical developers and clinical programs seeking novel oral anti‑inflammatory therapies for diseases such as rheumatoid arthritis, lupus, and age‑related inflammatory disorders.
Features
- Small‑molecule oral formulation that targets metabolic pathways in immune cells to reduce cytokine output
- Simultaneous inhibition of several pro‑inflammatory cytokines rather than single‑target blockade
- Modulation of mitochondrial function to reprogram immune cell activity
- Designed to avoid immunogenicity associated with protein‑based biologics
- Potential applicability across a range of inflammatory, autoimmune, and age‑related conditions